Ondansetron for treating alcohol use disorder

Ondansetron is currently in clinical development for the treatment of alcohol use disorder (AUD). AUD consist of disorders characterised by compulsive heavy alcohol use and loss of control over alcohol intake. AUD are some of the most prevalent mental disorders globally, especially in high-income and upper-middle-income countries; and are associated with high mortality and burden of disease, mainly due to medical consequences, such as liver cirrhosis or injury. Despite their high prevalence, AUD are undertreated partly because of the high stigma associated with them. The relapse rate of people with AUD is high with few effective treatment options available. Factors such as family circumstances, age, and social norms are said to influence alcohol misuse.